Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

McMaster researcher leads development of promising drug for inflammation

31.03.2010
Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) remain the most common treatment to relieve symptoms of arthritis and other inflammatory disorders.

But despite their widespread use (around 2.5 million Canadians have osteoarthritis) these medications are also known to cause severe, sometimes life-threatening adverse effects within the body, particularly in the gastrointestinal tract.

A novel anti-inflammatory drug being developed and commercialized by an inflammation expert at McMaster University has shown promise in relieving symptoms of inflammation, while substantially reducing the incidence of bleeding and intestinal damage often caused by NSAIDs.

The research is published in the March issue of the British Journal of Pharmacology.

John Wallace, a pharmacologist and director of the Farncombe Family Digestive Health Research Institute at McMaster University, compared naproxen, a commonly used NSAID, to a novel anti-inflammatory drug, ATB-346, which he developed in collaboration with a team of Italian chemists and is now commercializing through his company, Antibe Therapeutics Inc.

ATB-346 is a derivative of naproxen which releases hydrogen sulfide. Evidence from animal studies suggests that in small quantities, hydrogen sulfide can protect the stomach from injury and can accelerate the healing of pre-existing ulcers.

"I've been working on NSAIDs for over 20 years," said Wallace, a professor of medicine in the Michael G. DeGroote School of Medicine at McMaster University. "This particular drug is, by far, the shining star. We've tested it in every model where it should fail, and it has performed exceptionally well."

To examine the gastrointestinal safety and anti-inflammatory effectiveness of ATB-346, Wallace and his co-investigators tested the drug in healthy rats as well as those with arthritis and inflammation. The researchers also examined the impact of the drug on rats with compromised gastrointestinal tracts, a model which mimicked the clinical scenario in which NSAIDs are frequently used and have caused damage such as bleeding and ulcers.

"From the beginning, we decided that we were going to do the most rigorous testing of any NSAID that's ever been done," Wallace said. "We very deliberately tested the drug in models where NSAIDs fail."

The researchers found that ATB-346 was at least as effective as naproxen in relieving inflammation in animal models. They also discovered that ATB-346 was in the order of 100 times safer than naproxen, causing little or no damage to the stomach and small intestine.

When given to rats with impaired gastrointestinal tracts, ATB-346 did not cause any gastric damage. Moreover, the researchers observed that it enhanced, rather than inhibited, healing of pre-existing ulcers.

Finally, unlike naproxen, ATB-346 had no effect on blood pressure in rats with hypertension, suggesting the drug may have less cardiovascular risks than conventional NSAIDs.

The researchers concluded that H2S-releasing NSAIDs appear to represent a promising alternative to existing therapies for the treatment of inflammation and pain. Future research will focus on the potential cardiovascular benefits of these drugs.

Antibe Therapeutics was founded by Wallace in 2004. The company specializes in developing hydrogen sulfide-releasing drugs to treat inflammatory disorders.

About McMaster University

McMaster University, one of four Canadian universities listed among the Top 100 universities in the world, is renowned for its innovation in both learning and discovery. It has a student population of 23,000, and more than 140,000 alumni in 128 countries.

For more information, please contact:

Veronica McGuire
Media Relations Coordinator
Faculty of Health Sciences
McMaster University
905-525-9140, ext. 22169
vmcguir@mcmaster.ca

Veronica McGuire | EurekAlert!
Further information:
http://www.mcmaster.ca

More articles from Life Sciences:

nachricht Stiffness matters
22.02.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht Separate brain systems cooperate during learning, study finds
22.02.2018 | Brown University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Stiffness matters

22.02.2018 | Life Sciences

Magnetic field traces gas and dust swirling around supermassive black hole

22.02.2018 | Physics and Astronomy

First evidence of surprising ocean warming around Galápagos corals

22.02.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>